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Abstract
Background: Cardiovascular diseases (CVD) are a major cause of death in people with AIDS. Factors contributing to
atherosclerosis include traditional risk factors, antiretrovirals and inflammatory factors related to HIV infection. This
study set out to compare risk factors associated with subclinical atherosclerosis in individuals under and over
40 years of age.
Methods: Case–control study with 697 HIV/AIDS individuals without HAART or who remain on their first
antiretroviral regimen. Of the total, 351 individuals under 40 years and 346 over 40 years were analyzed separately.
Subclinical atherosclerosis was assessed by carotid intima-media thickness, using B-mode ultrasound. Multivariate
logistic regression was performed to find predictors of subclinical atherosclerosis in the entire group. Subsequent
analysis excluded patients with major risk factors for CVD. Magnitudes of associations were expressed by odds ratio
(OR) statistical significance, using a 95% confidence interval and p-value <0.05.
Results: In the <40 years group subclinical atherosclerosis was associated with male gender (OR: 2.77, 95% CI: 1.43–
5.34), nonwhite race (OR: 3.01, 95% CI: 1.23-6.53), obesity (OR: 5.13, 95% CI: 1.79–14.7) and metabolic syndrome
(OR: 3.30, 95% CI: 1.44–7.58). In the group ≥40 years predictors of subclinical atherosclerosis were overweight and
obesity (OR = 2.53, 95% CI, 0.85–7.54), current CD4 ≥350 cells/mL (OR: 2.81, 95% CI: 1.22–6.47) and NNRTI use
≥ 5 years (OR: 2.65, 95% CI: 1.10-6.37) or PI use >5 years (OR: 1.81, 95% CI: 0.38-8.59). In the multivariate model
excluding patients with major risk factors for CVD, age, male sex and nonwhite race were associated with
subclinical atherosclerosis in the <40 y group, while in the ≥40 y group, age, HIV viral load >10,000 copies and the
use of NNRTI (OR: 7.60, 95% CI: 1.61-35.8) or PI ≥5 years (OR: 3.62, 95% CI: 0.48-26.8) were associated with subclinical
atherosclerosis.
Conclusions: In young people the fight against obesity and metabolic syndrome is the main aim in the prevention
of CVD. In individuals aged ≥40 y, the prevention of obesity is also of great importance. Moreover, the effects of
uncontrolled viremia and the prolonged use of HAART appear to be more harmful in the older group.
Keywords: HIV, Risk factors, Atherosclerosis
* Correspondence: helramos@terra.com.br
1Department of Tropical Medicine, Universidade Federal de Pernambuco,
Recife, Brazil
2Department of Clinical Medicine, Universidade de Pernambuco, Recife, Brazil
Full list of author information is available at the end of the article
© 2013 Albuquerque et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Albuquerque et al. BMC Infectious Diseases 2013, 13:274
http://www.biomedcentral.com/1471-2334/13/274
Background
Cardiovascular diseases, especially coronary heart dis-
ease (CHD), have been the leading cause of mortality in
the general population [1] and have now also been iden-
tified as a major cause of death in people with AIDS [2].
However, while the association of atherosclerosis and
CHD in itself involves a complex inflammatory process,
the acquisition of chronic infection with human im-
munodeficiency virus (HIV) in the same individual adds
further complexity to this process. Thus, we have, firstly,
atherosclerosis that begins in childhood, characterized
by the presence of lymphocytes, foamy macrophages, in-
creased expression of adhesion molecules, proliferation
of smooth muscle cells, fat accumulation in the intima
layer of the arteries and plaque maturation lipids in the
blood vessels [3], and, secondly, endothelial injury
caused by HIV [4] itself and by the action of HAART
linked to inflammation [5].
Some authors also mention the great frequency with
which the well-known risk factors for CHD, namely a
family history of premature atherosclerotic disease,
smoking, hypertension, obesity and inactivity [6], are
found in these patients.
In addition, metabolic disorders like insulin resistance
and dyslipidemia induced by antiretroviral agents such
as protease inhibitors and nucleoside analogue reverse
transcriptase inhibitors are reported to be predictors of
cardiac events in these individuals [7]. Although factors
potentially contributing to this increased risk include
traditional CHD risk factors and antiretroviral medica-
tions, more recent data support a role for inflammatory
and immunologic factors as central to a complex mecha-
nism [8]. Decreasing CHD risk among HIV-infected pa-
tients is likely to involve the modification of inflammatory
and immunologic factors through antiretroviral therapy or
other novel strategies, as well as the targeted treatment of
traditional CHD risk factors [8-10].
In Brazil, the AIDS epidemic affects young people,
predominantly those aged from 20 to 39 years, systemat-
ically accounting for over 60% of all reported cases in
both sexes [11]. About 250,000 individuals infected with
HIV are on combined antiretroviral therapy [12], pro-
vided free of charge by the government. However, both
the magnitude with which atherosclerosis affects these
patients and the impact of the risk factors on the condi-
tion remain unknown.
In view of this, the present study, using carotid
intima-media thickness (IMT) as a marker of early
atherosclerosis in the vascular bed and as a predictor of
the development of atherosclerosis [13], was conducted
with the following two objectives: firstly, to estimate the
frequency with which subclinical atherosclerosis is
present in young adults with HIV/AIDS and in those
aged 40 years and over; and secondly, to evaluate the
association of the traditional risk factors for cardiovascu-
lar disease, as well as those related to HIV infection and
antiretroviral therapy, with subclinical atherosclerosis in
the two groups.
Methods
Study population, recruitment, and survey methods
A case–control study was carried out in a population of
697 patients, selected from a cohort of patients with
HIV/AIDS being screened for cardiovascular diseases in
the state of Pernambuco from July 2007 to January 2010,
who were treated at Hospital Oswaldo Cruz (University of
Pernambuco) and Hospital Correia Picanço (Pernambuco
State Department of Health).
The following inclusion criteria were adopted: age 18
years or older, individuals with no antiretroviral therapy
or on their first HAART regimen, absence of opportun-
istic disease in the three months up to the ultrasound
examination and no prior angina, heart failure or myo-
cardial infarction.
Cases were defined as individuals over 18 years with
subclinical atherosclerosis (IMT greater than 0.8 mm
and/or the presence of atheromatous plaques in the
carotid arteries identified by ultrasonography). Con-
trols were those aged over 18 years without subcli-
nical atherosclerosis.
We measured the frequencies of subclinical athero-
sclerosis and sex, race, schooling, stable partner, trad-
itional risk factors for CHD (smoking, family history of
early CHD, arterial hypertension defined according to
VIIJC [14], hyperglycemia (fasting glicemia ≥ 100 mg/dL),
metabolic syndrome, hypercholesterolemia (≥ 240 mg/
dL), low HDL-C (< 40 mg/dL in men and < 45 mg/dL in
women) and increased LDL-C (≥ 130 mg/dL), lipo-
dystrophy, hypertriglyceridemia (≥ 150 mg/dL), alcohol
use, drug use, as well as the frequency of factors related to
HIV/AIDS/HAART (time elapsed since diagnosis of the
infection/HIV disease, history of AIDS, viral load counts -
at the start of the study, CD4 count <350 cels/mm3- nadir
and at the start of the study, use and duration of use of
the antiretroviral regimen).
The study population was divided into two large
groups: those under 40 years of age (<40 y) and those
aged 40 years and over (≥40 y), each group being ana-
lyzed separately. The reasons for the cut-off point of 40
y were the following: 1) an exploratory analysis of data
showed that the chance of atherosclerosis was more than
10 times higher in the 40–49 y age group than in the
younger group, and that this chance was even higher in
people aged 50 y or over. We thought that, although we
could have adjusted our analysis by age, it would be
more informative to split the sample into these two
groups that might have important differences between
them and 2) the 40 y cut-off divided the population of
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the study down the middle (median age of the popula-
tion was 40 y).
Traditional and HIV-related risk factors
To obtain information on risk factors, a questionnaire
was applied in individual interviews by trained profes-
sionals. We also performed a detailed review of medical
records. Measurements of weight, height and waist cir-
cumference, as well as blood pressure, were obtained
during the interview using the health services’ own
equipment.
Serum glucose, total cholesterol, high density lipoprotein
(HDL), low density lipoprotein (LDL) and triglycerides as-
says were performed after blood collection following a
fasting period of 12 hours. For triglyceride levels below
400 mg/dL, LDL-cholesterol was calculated using the
Freidewald formula: LDL =TC − [HDL + (TG/5)] [15].
The CD4 lymphocyte count was performed by flow cy-
tometry (FACSCalibur - Multitest, San Jose, CA) and the
viral load determined by the ultrasensitive test
(Amplicor HIV-1 Monitor Assay, Roche Molecular Sys-
tems, Branchburg, NJ) , whose limits of detection are 50
to 750,000 RNA copies/mL up to six months from the
carotid artery ultrasound. The U.S. National Cholesterol
Educational Program (NCEP) ATP III [16] definition
was used for diagnosis of the metabolic syndrome.
The median time between the USG and the question-
naire was 35 days; between the USG and CD4 and viral
load (evaluated simultaneously) it was 96 days; and be-
tween the USG and triglycerides /cholestherol (evaluated
simultaneously) it was 28 days.
Measurement of IMT and carotid plaque
The measurements of IMT and determination of ather-
oma in the extracranial carotid wall were performed
using the high-resolution B mode ultrasound equipment
GE VIVID Five (Horten, Norway) with a linear trans-
ducer (7.5 MHz) and software specifically designed for
studying the arteries. The presence of atheroma was de-
fined as a focal prominence greater than 50% of the ves-
sel wall thickness on the adjacent segments and invading
the lumen [17]. Measurements of IMT were obtained on
the anterior and posterior walls of the right and left ca-
rotid [18] arteries as follows: three measurements on the
carotid artery one centimeter proximal to the bifur-
cation, one measurement in the carotid bulb and two
measurements in the first inch of the internal carotid ar-
tery. For the final analysis we used the maximum mean
of the thickness of each segment. Subclinical atheroscler-
osis was considered to be present when the thickness of
the carotid intima-media was ≥ 0.8 mm and/or in the
presence of an atheroma plaque in any carotid segment.
We chose the same cut-off of 0.8 mm for evaluation of
carotid atherosclerosis as that used by Jerico et al. [19].
This choice was based on the fact that the measurement
of the common carotid IMT in a normal population of
young adults produces values lower than 0.8 mm [20],
with an increase from 0.01 to 0.02 mm per year. In
addition, individuals with a carotid IMT lower than 0.8
mm have less risk of cardiovascular and cerebrovascular
events (<4.6%) in six years [21]. Given that the median
age of the study population was 40 years, the 0.8 mm
cut-off seemed to be a rational choice.
To minimize bias, the following measures were
adopted: a precodified standardized questionnaire and
training of all the interviewers in order to standardize
techniques; selection of controls from the same popula-
tion established for cases, provided that both groups sat-
isfied the same inclusion and exclusion criteria; and
masking the ultrasound technicians in relation to the
traditional risk factors for cardiovascular disease (CVD),
status and HIV therapy.
For quality control of the imaging examination 480 re-
peated measurements of IMT thickness were made,
resulting in an inter-class correlation coefficient of 0.866
and a Kappa concordance index of 0.895.
Data analysis
Univariate and multivariable logistic regression analysis
was performed using the statistical package STATA ver-
sion 9.0 to identify potential predictors of subclinical
atherosclerosis, assessed separately in the two groups
(<40 y and 40≥ y).
The insertion of the data was carried out by double
entry, under weekly supervision, thus avoiding transcrip-
tion errors. Backup copies of the definitive database
were made on CD-ROM and subsequently submitted to
consistency tests.
Medians were compared using the nonparametric test
of Kruskall-Wallis. Comparisons between the groups of
categorical variables were performed using the chi-
square test and, when necessary, the Fisher Exact test.
Logistic regression was used to calculate crude and ad-
justed odds ratios of the association between the inde-
pendent variables and the outcome, with the respective
95% confidence intervals (CI) and p-values (likelihood
ratio statistic).
The data analysis was carried out in three steps: 1)
univariate analysis of each group to determine the vari-
ables closely associated with the outcome: variables asso-
ciated with the outcome with P < 0.20 in the univariate
analysis were successively included in a multivariate lo-
gistic regression model; 2) final multivariate model: the
variables selected in the previous step were inserted into
the final multivariate model using the forward selection
(including the entire group of patients), and those with a
p-value ≤ 0.10 remained in the final model; and 3) a subse-
quent multivariate logistic regression of factors associated
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with subclinical atherosclerosis was carried out with the
exclusion of patients with traditional metabolic risk factors
for CVD and smoking, using a forward strategy similar to
that used previously.
Several models were tested in the multivariable ana-
lysis, and in those which included the metabolic syn-
drome variable (composite variable) the variables
comprising this syndrome were not included in the
analysis.
The study was approved by the Ethics and Research
Committee of the University of Pernambuco (UPE) and
free and informed written consent was obtained from all
participants.
Results
Characteristics of the study participants according to
age group
A total of 697 individuals were studied, 351 in the < 40 y
group and 346 in the ≥ 40 y group (Table 1). The mean
age was 31.8 years in the former and 47.8 years in the
latter. There were no differences between groups regar-
ding sex distribution, proportion of white race, smoking
Table 1 Comparison of qualitative and quantitative variables in HIV-infected individuals according to age group,
followed in two referral hospitals in the state of Pernambuco, Brazil
Variables < 40 years (n=351) ≥ 40 years (n=346) p-value
Sociodemographics
Age (years) – Mean (SD) 31.8 (4.96) 47.8 (6.14) < 0.001
Male (%) 59.5 57.8 0.641
White (%) 25.6 24.9 0.811
Stable partner (%) 19.4 24.3 0.117
Habits
Smoking (%) 23.0 22.0 0.725
Alcohol consumption (%) 40.4 35.2 0.167
Injecting drugs use (%) 6.0 3.8 0.368
Clinical characteristics
Diabetes (%) 0.9 6.2 < 0.001
Lipodystrophy (%) 31.5 39.8 0.024
Dyslipidemia (%) 16.1 31.7 < 0.001
Metabolic syndrome (%) 16.9 31.3 < 0.001
HIV-related characteristics
Time elapsed since diagnosis HIV (in months -DP) 40.5 (37.5) 58.4 (49.6) < 0.001
CD4 T-lymphocytes baseline - Median (P25 – P75) 323 (158 – 498) 258 (94 – 473) 0.005*
Viral load baseline - Median (P25 – P75) 29600 (3341 – 134000) 57400 (6170 – 205000) 0.026*
CD4 T-lymphocytes current - Median (P25 – P75) 391 (262 – 535) 383 (242 – 564) 0.949*
Viral load, current undetectable (%)** 31.7 46.7 0.005
HAART duration (in months) Median (P25–P75) 23.5 (9.9 – 42.6) 36.3 (17.7 – 65.2) < 0.001*
NNTRI Use (%) 36.6 47.1 0.005
PI use (%) 21.7 26.9 0.112
Without HAART (%) 41.3 25.7 < 0.001
Laboratory tests
Total cholesterol (mg/dL) - Mean (SD) 163.5 (40.0) 189.6 (54.5) < 0.001
LDL cholesterol (mg/dL) - Mean (SD) 93.9 (38.8) 106.7 (40.8) 0.001
HDL cholesterol (mg/dL) - Mean (SD) 42.2 (13.6) 43.5 (14.1) 0.216
Triglycerides (mg/dL) - Mean (SD) 148.8 (102.8) 204.6 (213.0) < 0.001
USG of carotid arteries
Presence of sublinical atherosclerosis (%) 23.4 66.5 < 0.001
Carotid intima thickness (mm) - Median (SD) 0.742 (0.084) 0.841 (0.150) < 0.001
* Kruskal - Wallis test.
** 328 patients with viral load information.
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or drug use. A total of 312 individuals had subclinical
atherosclerosis, of whom 82 (23.4%) were in the < 40 y
group, whose mean IMT thickness was 0.742 mm, and
230 (66.5%) in the ≥ 40 y group, whose mean IMT thick-
ness was 0.841 mm, representing a statistically signifi-
cant difference between the groups (p <0.001).
Diabetes (6.2%), lipodystrophy (39.8%), metabolic syn-
drome (31.3%) and dyslipidemia (31.7%) were more fre-
quent in the ≥ 40 y group. The mean values of total
cholesterol (189.6 mg/dL), LDL cholesterol (106.7 mg/dL)
and triglycerides (204.6 mg/dL) were higher in the ≥ 40 y
group, except for mean HDL cholesterol, for which there
were no statistical significant differences between the
groups (p = 0.216).
A total of 31.7% of those on HAART in the < 40 y
group had an undetectable viral load, and the corre-
sponding figure was 46.7% in the ≥ 40 y group (p =
0.005), with a median of CD4 391 cells/μl in the former
group and 383 cells/μl in the latter. The < 40 y group had
been using HAART for less time (median, 23.5 months)
than the ≥ 40 y group (median, 36.3 months) (p <0.001).
Values of carotid IMT in the two different age groups
In the group of patients < 40 years the median of the ca-
rotid IMT was higher in patients on HAART than in
those without therapy (p=0.069) and in those with
duration of use of HAART ≥5 years (p=0.015), while no
differences were found in patients in different strata of
CD4, viral load and types of antiretroviral regimen. In
the ≥ 40 y group carotid IMT was greater in patients
with higher CD4 strata (p=0.011), and in those on
HAART for ≥ 5 years (0.070). There were no differences
in the carotid IMT in all viral load strata and different
types of antiretroviral regimen (Table 2).
Association between subclinical atherosclerosis and
demographic, clinical, laboratory and HIV-related
characteristics in the different age groups
Tables 3 and 4 summarize the results of the univariate
analysis in relation to the association of the variables
with the presence of subclinical atherosclerosis. In the
< 40 y age group, male gender, nonwhite race, stable
partner, hypertension, cholesterol ≥ 240 mg/dL, tri-
glicerydes ≥ 150 mg/dL, fasting glucose ≥ 100 mg/dL,
waist circumference, overweight and obesity were signifi-
cantly associated with subclinical atherosclerosis after ad-
justment for age. No significant differences were found
with other risk factors for CVD such as smoking and HDL
or LDL-cholesterol. The ≥ 40 y group presented a statisti-
cally significant difference for age, stable partner, hyper-
tension, overweight, obesity and, and also for altered levels
of total cholesterol and LDL cholesterol. As regards the
Table 2 Values of the carotid intima media thickness (IMT) of the patients < 40 years and ≥ 40 years
Variables < 40 y group ≥ 40 y group
Carotid MIT Median (P25; P75) p-value Carotid MIT Median (P25; P75) p-value
HAART use p = 0.069 p = 0.166
Yes 0.735 (0.691; 0.792) 0.840 (0.772; 0.917)
No 0,722 (0.677; 0.780) 0.827 (0.740; 0.915)
CD4 T-lymphocytes (cells/mm3) p = 0.373 p = 0.011
<200 0.720 (0.685; 0.782) 0.797 (0.742; 0.964)
200 to 350 0.728 (0.681; 0.792) 0.822 (0.760; 0.919)
≥ 350 0.731 (0.693; 0.779) 0.852 (0.802; 0.920)
Viral load (copies/mL) p = 0.269 p = 0.616
< 50 0.745 (0.677; 0.822) 0.836 (0.765; 0.135)
50 to < 10.000 0.742 (0.705; 0.795) 0.837 (0.757; 0.940)
10.000 to < 100.000 0.723 (0.681; 0.769) 0.852 (0.763; 0.922)
≥ 100,000 0.690 (0.682; 0.741) 0.831 (0.775; 0.918)
Types HAART regimens p = 0.109 p = 0.132
No HAART use 0.722 (0.677; 0.780) 0.827 (0.740; 0.915)
PI 0.733 (0.690; 0.767) 0.782 (0.732; 0.875)
NNRTI 0.729 (0.696; 0.784) 0.837 (0.778; 0.897)
Duration of use of HAART p = 0,015 p = 0.070
No use 0.722 (0.677; 0.780) 0.827 (0.740; 0.915)
< 5 years 0.730 (0.690; 0.790) 0.830 (0.757; 0.918)
≥5 years 0.757 (0.730; 0.815) 0.864 (0.805; 0.915)
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Table 3 Univariate analysis of the association between subclinical atherosclerosis and socio-demographic variables,
habits, and metabolic data in individuals infected with HIV by age group, seen at two referral hospitals in the state of
Pernambuco, Brazil
Variables < 40 years old (n=351) ≥ 40 years old (n=346)
% subclinical
atherosclerosis
OR(CI) p-value % subclinical
atherosclerosis
OR(CI) p-value
Age (continuous) - 1.17 (1.10 – 1.25) < 0.001 - 1.11 (1.06 – 1.16) < 0.001
Gender
Female 18.3 1.0 - 62,7 1.0 -
Male 26.8 1.63 (0.96 – 2.75) 0.067 69.2 1.33 (0.84 – 2.09) 0.213
Race
White 13.3 1.0 - 68.2 1.0 -
Nonwhite 26.8 2.38 (1.22 – 4.64) 0.011 65.9 0.89 (0.53 – 1.52) 0.691
Schooling (years of study)
1 to 12 22.3 1.0 - 66.4 1.0 -
13 or more 32.3 1.67 (0.77 – 3.59) 0.190 68.3 1.10 (0.58 – 2.10) 0.759
Stable partner
No 20.1 1.0 - 62.5 1.0 -
Yes 36.8 2.30 (1.30 – 4.08) 0.004 78.6 2.19 (1.23 – 3.91) 0.008
Smoking
No 24.4 1.0 - 66.4 1.0 -
Yes 19.8 0.87 (0.36 – 2.09) 0.759 66.7 0.97 (0.46 – 1.93) 0.929
Lipodystrophy
No 20.6 1.0 - 63.5 1.0 -
Yes 28.0 1.50 (0.88 – 2.54) 0.131 70.2 1.35 (0.84 – 2.17) 0.206
Metabolic Syndrome
No 17.9 1.0 - 63.9 1.0 -
Yes 49.1 4.42 (2.44 – 7.99) 0,000 72.0 1.44 (0.87 – 2.38) 0.147
Hypertension
No 19.1 1.0 - 61.0 1.0 -
Yes 44.3 3.36 (1.87 – 6.03) 0.000 76.9 2.12 (1.28 – 3.52) 0.004
Waist circumference (cm)
Normal 19.2 1.0 - 62.3 1.0 -
Abnormal* 41.2 2.94 (1.66 – 5.18) 0.000 74.7 1.64 (0.93 – 2.89) 0.087
BMI (kg/m2)
< 25 15.5 1.0 - 60.0 1.0 -
≥ 25 and < 30 32.6 2.63 (1.49 – 4.67) 0.001 75.2 2.02 (1.19 – 3.42) 0.008
≥ 30 52.9 6.14 (2.86 – 13.2) 0.000 81.2 2.88 (1.13 – 7.32) 0.025
Total cholesterol (mg/dL)
< 200 21.7 1.0 - 62.6 1.0 -
200 - <240 28.6 1.44 (0.69 – 2.98) 0.323 69.4 1.35 (0.79 – 2.32) 0.269
≥ 240 42.1 2.62 (1.01 – 6.80) 0.048 83.0 2.89 (1.22 – 6.84) 0.015
HDL-cholesterol (mg/dL) **
Normal 24.8 1.0 - 64.8 1.0 -
Low 22.4 0.87 (0.52 – 1.44) 0.596 67.7 1.13 (0.72 – 1.79) 0.579
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variables related to HIV, a statistically significant associ-
ation was observed with CD4 counts > 350 cells/mL,
the use of nonnucleoside reverse-transcriptase inhibi-
tors (NNRTIs) for more than 5 years. However we
found no significant differences in the virological sta-
tus of HIV.
The multivariate model of the associations of demo-
graphic factors, traditional risk factors for CVD and HIV
infection with the presence of subclinical atherosclerosis
in 697 patients is presented in Table 5. The independent
predictors of subclinical atherosclerosis in the < 40 y
group were age, male sex, nonwhite race, stable partner,
obesity and metabolic syndrome, and in the ≥ 40 y group
they were age, male sex, stable partner, obesity, total
cholesterol > 240 mg/dL, CD4 lymphocyte count > 350
cells/μl and duration on NNRTI ≥ 5 years. Obesity and
hypertension presented an association with the presence
of subclinical atherosclerosis, but nullified each other
when introduced into the multivariate model. Thus
hypertension was withdrawn from the final model, since
obesity is related to the genesis of hypertension.
In order to verify if an HIV-related effect was masked
by traditional risk factors for atherosclerosis two new
multivariate models were prepared. The first model was
prepared excluding the individuals with the major trad-
itional risk factors that were significant in the overall
final model, entitled Model A, resulting in the exclusion
of 333 patients as follows: patients with metabolic syn-
drome (n=166); obese individuals (n=20); hypertensives
(n=77); patients with total cholesterol ≥ 240 mg/dL
(n=24) and smokers (n=46). The results of the multivari-
ate Model A demonstrated that, in the <40 y group, age,
male sex and nonwhite race were associated with sub-
clinical atherosclerosis. In the ≥ 40 y group, age, viral
load ≥ 10,000 or 100,000 copies RNA/mL and time on
PI ≥ 5 years (OR: 3.62) or time on NNRTI ≥ 5 years
(OR: 7.60) remained as factors independently associated
with carotid atherosclerosis. The other multivariate
model, entitled Model B, comprised all 333 patients
with the major traditional risk factors for cardiovascular
disease excluded from Model A. In this multivariate final
Model B, among patients ≥ 40 years, those with CD4
levels ≥ 350 lymphocytes/mm3 had a 10.8 higher risk
(95% CI: 2.89 – 40.4; p < 0.001) of presenting subclinical
atherosclerosis. Viral load was not associated with
atherosclerosis in this group. The use of HAART was
not related to atherosclerosis, except for the use of
NNRTI < 5 years.
Discussion
In our study differences in the magnitude and signifi-
cance of associations between risk factors and subclinical
atherosclerosis were observed between the groups,
starting with the higher frequency of atherosclerosis
(66.5%) in the ≥ 40 y group than in the < 40 y group
(44.8%). In patients with HIV/AIDS in the < 40 y group
it was the traditional risk factors such as male sex, non-
white race, obesity, metabolic syndrome and hyperchol-
esterolemia that were associated with subclinical
atherosclerosis. In the ≥ 40 y group, male sex, over-
weight and obesity were also associated with subclinical
atherosclerosis; however, factors related to HIV and
HAART (CD4 above 350 cells/mL and use of NNRTI
for at least 5 years) were also associated with subclinical
atherosclerosis in this age group. Age and stable partner
were independent predictors of subclinical atheroscler-
osis in both groups. Analyzing only patients without
major modifiable risk factors related to cardiovascular
disease, only age, male sex and nonwhite race seemed to
be important with regard to the presence of subclinical
atherosclerosis in the < 40 y group, while in the ≥ 40 y
group, age, viral load and the use of NNRTI ≥ 5 years
were independently associated with the presence of ath-
erosclerosis. In the group of persons with at least one
modifiable risk factor for CVD and ≥ 40 y, patients with
Table 3 Univariate analysis of the association between subclinical atherosclerosis and socio-demographic variables,
habits, and metabolic data in individuals infected with HIV by age group, seen at two referral hospitals in the state of
Pernambuco, Brazil (Continued)
LDL-cholesterol (mg/dL)
< 130 22.2 1.0 - 61.5 1.0 -
≥ 130 30.4 1.53 (0.77 – 3.05) 0.225 82.9 3.02 (1.58 – 5.82) 0.001
Triglycerides (mg/dL)
< 150 18.9 1.0 - 63.9 1.0 -
≥ 150 31.4 1.96 (1.17 - 3.28) 0.010 69.3 1.27 (0.80 – 2.01) 0.296
Fasting glucose (mg/dL)
< 100 21.6 1.0 - 65.6 1.0 -
≥ 100 35.7 2.01 (1.01 – 4.01) 0.046 72.4 1.39 (0.81 – 2.38) 0.227
*Men: waist >102 cm; women: waist >88 cm.
**Low HDL-cholesterol < 40 mg/dL in men and < 45 mg/dL in women.
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levels ≥ 350 lymphocytes/mm3 had a 10.8 higher risk of
having subclinical atherosclerosis.
Understanding the risk of cardiovascular disease in in-
dividuals with HIV is a complex matter. Since the intro-
duction of HAART, cardiovascular events resulting from
atheromatous complications have been reported [22,23],
but it is not known to what extent this risk is attribu-
table to the therapy and its adverse effects or to genetic
factors, traditional risk factors or even to the inflamma-
tory state associated with HIV [24].
The measurement of CMIT thickness has been in-
creasingly used as a surrogate marker of atherosclerosis
due to the long time required for the appearance of cli-
nical events. A systematic review and meta-analysis
showed the high predictive capacity of the measurement
of CMIT to predict future cardiovascular events such as
myocardial infarction and stroke in the general popula-
tion [25]. The CMIT thickness among HIV-positive pa-
tients is higher than among HIV-negative ones and HIV
infection is an independent risk factor for the presence
of carotid thickening [26-28] and its progression [26].
Our study aimed to examine whether the risk factors
associated with increased thickening of CMIT in HIV-
infected individuals are different between individuals
aged below 40 years and those 40 years or more. This
question arose as the exploratory analysis of our data
showed that the chance of atherosclerosis was more than
10 times higher in the 40–49 y age group than in the
younger group, and that this chance was even higher in
people aged 50 y or over. We decided that, although we
could have adjusted our analysis by age, it would be
more informative to split the sample into these two
Table 4 Univariate analysis of the association between subclinical atherosclerosis and other factors related to HIV, by
age group, seen at two referral hospitals in the state of Pernambuco, Brazil
Variables < 40 years old (n=351) ≥ 40 years old (n=346)
% subclinical
atherosclerosis
OR(CI) p-value % subclinical
atherosclerosis
OR(CI) p-value
Time elapsed since HIV diagnosis (years)
< 1 19.3 1.0 - 55.1 1.0 -
1 to < 5 22.3 1.19 (0.64 – 2.25) 0.570 65.8 1.56 (0.81 – 3.01) 0.179
≥5 30.5 1.82 (0.91 – 3.66) 0.090 70.6 1.95 (0.99 – 3.83) 0.051
Clinical history of AIDS
No 24.0 1.0 - 65.7 1.0 -
Yes 24.2 1.01 (0.58 – 1.76) 0.975 72.7 1.38 (0.68 – 2.81) 0.362
CD4+ T-lymphocytes (cells/mm3)
< 200 22.2 1.0 - 53.3 1,0 -
200 to < 350 24.4 1.12 (0.51 – 2.48) 0.763 63.1 1.49 (0.81 – 2.74) 0.193
350 and more 21.9 0.98 (0.42 – 2.30) 0.963 84.0 4.59 (2.19 – 9.59) 0.000
Viral load (copies/mL)
< 50 29.4 1.0 - 67.5 1.0 -
50 to < 10,000 24.6 0.78 (0.34 – 1.81) 0.566 62.7 0.89 (0.41-1.91) 0.767
10,000 < 100,000 19.4 0.58 (0.21 – 1.61) 0.295 72.7 1.61 (0.54-4.73) 0.384
> 100,000 15.4 0.44 (0.09 – 2.21) 0.316 68.6 1.07 (0.32-3.55) 0.905
HAART use
No 19.9 1.0 - 59.5 1.0 -
Yes 26.0 1.42 (0.85 – 2.36) 0.184 68.9 1.50 (0.91 – 2.48) 0.109
Types HAART regimens
No HAART use 19.9 1.0 - 59.5 1.0 -
PI 17.1 0.83 (0.40 – 1.71) 0.619 59.3 0.99 (0.54 – 1.79) 0.977
NNRTI 31.2 1.83 (1.05 – 3.19) 0.031 74.2 1.95 (1.12 – 3.39) 0.017
HAART duration of use (years)
No HAART use 19.9 1.0 - 59.5 1.0 -
< 5 24.7 1.32 (0.78 - 2.25) 0.299 64.2 1.21 (0.72 – 2.06) 0.460
≥ 5 34.6 2.13 (0.86 – 5.27) 0.100 81.6 3.00 (1.46 – 6.16) 0.003
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groups, bearing in mind that there might be important
differences between them. Another point reinforced our
decision, namely the fact that the 40 y cut-off divided
our population down the middle (the median age of the
population was 40 y).
Our overall results showed that both traditional and
new risk factors (albeit not related to HIV) were strongly
associated with the onset of carotid thickening, particu-
larly in the younger population. Thus, male sex, non-
white race, obesity, metabolic syndrome and elevated
levels of total cholesterol were associated with the
presence of thickening of CMIT in the group < 40 y.
This result is in agreement with studies that assessed
thickening of CMIT in HIV-positive individuals,
which also found the traditional risk factors related to
CVD to be the main factors associated with increased
CMIT [24,26,29].
The metabolic syndrome was detected in 16% of the
younger group and in 31% of ≥ 40 y group of our study.
In the general population, the metabolic syndrome is as-
sociated with a 2.35-fold greater risk of developing CVD
[30] and was an independent factor associated with
greater CIMT in younger patients in our study. In the
population with HIV, the metabolic syndrome is de-
scribed as a possible complication of the use of HAART,
especially in regimens containing a protease inhibitor
[31], and might or might not be suggestive of an indirect
effect of HAART in atherogenesis. Nonetheless, in an
analysis that included 331 antiretroviral treatment-naive
patients conducted by Stein et al., the metabolic syn-
drome was also an important factor in the presence of
carotid lesions [32], suggesting that the role of the meta-
bolic syndrome in CMIT thickening is not necessarily
related to the use of HAART.
With regard to obesity as a predictor of CVD risk, our
study was in agreement with the literature in an at-risk
population not infected by HIV, which reported a linear
relationship with thickening of the CIMT in young obese
individuals [33].
In the final model of the multivariable analysis of all
patients in each age group, no factor related to HIV or
its treatment was associated with CMIT thickening in
the < 40 y group. On the other hand, the group of indi-
viduals 40 years or more, levels of CD4 > 350 lympho-
cytes/mm3 and the use of NNRTI > 5 years were
associated with CMIT thickening.
One hypothesis is that the role of the traditional risk
factors is so important that it was not possible to iden-
tify factors specifically related to HIV or to HAART as
being associated with the disease, particularly in the
Table 5 Multivariate model of the association between subclinical atherosclerosis with sociodemographic variables,
habits, family history, clinical parameters, lipid profile, fasting glucose and features related to HIV by age group
including all patients (total of 694 patients)
Variables < 40 years old ≥ 40 years old
OR(IC) p-value OR(CI) p-value
Age (continuous) 1.12 (1.05 – 1.20) 0.001 1.11 (1.05 – 1.17) < 0.001
Male sex 2.77 (1.43 – 5.34) 0.002 1.62 (0.94 – 2.81) 0.080
Nonwhite 3.01 (1.23 - 6.53) 0.007 1.37 (0.73 – 2.57) 0.321
BMI overweight 1.65 (0.79 – 3.44) 0.344 1.93 (1.04 – 3.57) 0.036
Obese 5.13 (1.79 – 14.7) 0.002 2.53 (0.85 – 7.54) 0.095
Metabolic Syndrome 3.30 (1.44 – 7.58) 0.005 1.01 (0.54 – 1.88) 0.968
Total cholesterol <200 1.0 1.0
200 to < 240 mg/dL 0.83 (0.32 - 2.03) 0.701 1.24 (0.66 – 2.32) 0.491
≥ 240 mg/dL 2.28 (0.83 – 9.40) 0.095 2.14 (0.76 – 5.98) 0.145
Stable partner 2.07 (1.03 – 4.19) 0.041 2.41 (1.24 – 4.67) 0.009
CD4+ T-lymphocytes <200 1.0 1.0
200 to < 350 cels/mm3 0.86 (0.33 – 2.24) 0.758 1.18 (0.59 – 2.37) 0.631
≥ 350 cels/mm3 0.71 (0.24 – 2.09) 0.542 2.81 (1.22 – 6.47) 0.015
HAART duration of use
No HAART use 1.0 1.0
PI < 5 years 0.64 (0.27 – 1.54) 0.323 0.67 (0.32 – 1.39) 0.287
PI ≥ 5 years 2.15 (0.23 – 20.1) 0.503 1.81 (0.38 – 8.59) 0.453
NNRTI < 5 years 1.52 (0.74 – 3.08) 0.248 1.31 (0.66 – 2.60) 0.426
NNRTI ≥ 5 years 1.94 (0.62 – 6.07) 0.254 2.65 (1.10 – 6.37) 0.028
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younger group. This question was assessed by excluding
all the patients that presented at least one modifiable
risk factor unrelated to HIV (obesity, metabolic syn-
drome, hypertension, cholesterol above 240mg/dL and
smoking) in order to check whether some factor related
to HIV could be masked. In this important analysis
(Table 6, Model A) we found that among patients < 40 y
the results were similar, with no association between
CMIT thickening and HIV-related factors.
However important HIV-related factors in the group
of patients ≥ 40 y became even clearer after the exclu-
sion of patients with modifiable risk factors unrelated to
HIV. The first such finding was the association of the
higher CIMT with the use of antiretroviral therapy for
more than 5 years. This finding was particularly evident
when using NNRTI > 5 years (OR: 7.6), but was also
suggested when using PI > 5 years (OR: 3.62) although
the low number of patients using PI > 5 years in this
group did not permit any firm conclusion (only 16
observations).
The second important finding was the association of
thickening of CMIT with viremia ≥ 10.000 copies. The
levels of association were shown to be higher the higher
the category of viral load. HIV viremia is related to in-
flammation [8,24], a potent trigger for atherosclerosis
[3,8]. This finding is in agreement with that obtained by
Baker et al., who assessed the factors associated with
progression of CMIT thickening in 389 HIV-infected pa-
tients after adjustment for traditional risk factors. They
found that low baseline viral load (< 400 RNA copies / mL)
and the maintenance of viral load supression have been
associated with lower thickening of CMIT after a period of
2 years [34].
Thus, despite the heavy weight of traditional factors in
the presence of carotid thickening, the chronic use of
HAART and high levels of viremia are independent
factors for its occurrence, particularly in patients aged
40 years or more.
It might be assumed that a vessel in the process of ath-
erosclerosis "inherent in aging” would suffer a greater
impact with the prolonged use of HAART than the still
“healthy” vessels of the young. It might also be assumed
that there is a synergic action of the process of athero-
sclerosis “inherent in aging”, together with other factors
related to the therapy that are yet to be clearly identified.
However, the association of atherosclerosis specifically
with the use of a PI suggested in previous studies was
not observed in our population in either group of pa-
tients. This result was consistent with CMIT data from
337 patients, in whom no association was found between
Table 6 Multivariate model of factors related to the presence of subclinical atherosclerosis among 361 individuals
without the main risk factors for cardiovascular disease (CVD) (excluding a total of 333 patients = 166 patients with
metabolic syndrome, 20 obese patients, 77 hypertensive patients, 24 individuals with total cholesterol ≥ 240 mg /dL
and 46 smokers) (Model A) and among 333 patients with risk factors for cardiovascular diseases (Model B)
Variables Multivariate Model A (n=361) Multivariate Model B (n=333)
< 40 years old (n=218) ≥ 40 years old (n=143) < 40 years old (n=133) ≥ 40 years old (n=200)
OR(CI) p-value OR(CI) p-value OR(CI) p-value OR(CI) p-value
Age (continuous) 1.09 (1.00 – 1.19) 0.037 1.15 (1.06 – 1.25) 0.000 1.21 (1.08 – 1.36) 0.001 1.12 (1.04 – 1.21) 0.003
Male sex 3.02 (1.20 – 7.59) 0.018 1.03 (0.45 – 2.34) 0.937 1.59 (0.64 – 3.95) 0.311 2.53 (1.16 – 5.51) 0.019
Nonwhite race 3.21 (0.90 – 11.4) 0.071 1.23 (0.42 – 3.67) 0.702 2.59 (0.96 – 6.99) 0.060 1.28 (0.55 - 2.99) 0.557
Stable partner 1.62 (0.64 – 4.08) 0.306 3.97 (1.46 – 10.8) 0.007 3.14 (1.13 – 8.72) 0.028 2.04 (0.78 – 5.36) 0.144
CD4+ T-lymphocytes <200 1.0 1.0 1.0 1.0
200 to < 350 cels/mm3 1.07 (0.35 – 3.23) 0.902 0.97 (0.34 – 2.79) 0.967 0.51 (0.07 – 3.38) 0.486 2.52 (0.85 – 7.48) 0.094
≥ 350 cels/mm3 0.49 (0.12 – 1.98) 0.321 2.41 (0.68 – 8.47) 0.168 0.82 (0.11 – 5.79) 0.847 10.8 (2.89 – 40.4) 0.000
Undetectable Viral Load 1.0 1.0 1.0 1.0
50 to < 10,000 0.96 (0.24 – 3.78) 0.954 2.16 (0.50 – 9.37) 0.300 0.48 (0.09 – 2.40) 0.378 0.54 (0.15 – 1.98) 0.355
10,000 to < 100,000 0.47 (0.07 – 2.93) 0.425 5.95 (1.00 – 35.3) 0.050 0.83 (0.11 – 6.28) 0.863 1.46 (0.23 – 9.11) 0.681
≥ 100,000 0.33 (0.02 – 4.08) 0.394 6.84 (0.90 – 51.8) 0.063 0.27 (0.00 –12.77) 0.512 0.91 (0.10 - 7.80) 0.933
HAART duration of use
No HAART use 1.0 1.0 1.0 1.0
IP < 5 years 0.51 (0.15 – 1.75) 0.290 0.47 (0.137 – 1.66) 0.245 0.75 (0.19 – 2.87) 0.682 1.72 (0.60 – 4.89) 0.307
IP ≥ 5 years - - 3.62 (0.48 – 26.8) 0.208 0.87 (0.05-15.65) 0.925 -
NNRTI < 5 years 0.55 (0.18 – 1.62) 0.281 1.79 (0.57 – 5.59) 0.316 2.84 (0.92-8.68) 0.067 2.01 (0.71 – 5.71) 0.189
NNRTI ≥ 5 years 2.41 (0.59 – 9.82) 0.218 7.60 (1.61 – 35.8) 0.010 0.24 (0.02-2.53) 0.236 2.04 (0.63 - 6.58) 0.229
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the use of PI and CMIT thickening [35], and with the
findings of a meta-analysis that evaluated the association
of regimens containing PI and subclinical atherosclerosis
and, as in our study, revealed no associations with this
group of drugs [36].
However two of the results related to the use of
HAART in the group aged < 40 y deserve attention: a)
there was an association between the median of IMT
and HAART use (with a borderline p-value) and dur-
ation of use of HAART, though the median value of
IMT was below the cut-off point adopted in our study;
and b) there was no statistically significant association
between HIV-related factors and subclinical atheroscle-
rosis, though the lack of association with use of NNRTI
> 5 years may be due to a problem of power, as sug-
gested by the width of the confidence interval. These
data suggest that the use and type of HAART may have
some impact on the development of atherosclerosis in
this age group, an aspect of the present study that does
not allow any firm conclusions.
Our study found an association between a high
lymphocyte count and a greater chance of presenting
subclinical atherosclerosis in the ≥ 40 y group; however,
this effect disappeared after we excluded those patients
with metabolic risk factors for CVD. One possible ex-
planation is that patients who were immunologically
compensated (particularly when using HAART), i.e. with
high levels of CD4 lymphocytes, are more liable to have
traditional metabolic complications such as obesity, meta-
bolic syndrome and hypertension and, consequently, a
higher risk of presenting subclinical atherosclerosis
[37,38]. Hsue has shown that the rate of progression of
CMIT thickening was predicted by the CD4 nadir count
[26]. However, as in our findings, baseline, nadir or
present CD4 lymphocytes count were not associated with
the progression of CMIT thickness in the study by Baker
(2011) [34] or with CMIT thickness in antiretroviral naïve
individuals in the study by Stein (2012) [24].
Finally, in the older group, obesity was also a major
factor associated with atherosclerosis, as in the younger
one, which should alert us to the importance of fighting
it in HIV patients of all ages.
All the studies reported in the literature, including our
own, have shown that age is an independent factor asso-
ciated with CMIT thickening [24,34,35]. Nonetheless,
unlike previous studies, in which the authors adjusted
the risk factors for CMIT by age in their final model of
multivariable analysis [24,34], the population in our
study was split into two groups, an approach that clearly
shows the differences in their respective risk factors.
This study has the limitations of not having included
controls not infected with HIV and of not having
assessed the intensity of immune activation using bio-
markers of inflammation. Another limitation related to
the nature of the study is that time is an important fac-
tor that was not addressed. Those < 40 y probably had
less exposure to both traditional and HIV-related risk
factors. For example, taking a hypertensive participant
from both groups and assuming the hypertension (or
HIV for that matter) developed at about the same age,
the participant in the > 40 y group would have had lon-
ger exposure to hypertension (or viremia). This is im-
portant in that it distinguishes between hypertension (or
viremia) as a relevant risk factor in the < 40 y group as
opposed to exposure to hypertension over time as a risk
factor. Given the nature of the study, it is unlikely that
this effect can be accounted for statistically.
However one major advantage of our study compared
to others should be emphasized, namely the inclusion of
individuals on a single antiretroviral regimen, that is,
with no change in the class of drug throughout the treat-
ment, a feature that ensures the "purity" of the study
with regard to the evaluation of the association of drug
classes with atherosclerosis. Another advantage was the
elaboration of a model excluding patients with major risk
factors for atherosclerosis, for this offers an opportunity to
specifically examine the immunologic, virologic and thera-
peutic factors involved in subclinical atherosclerosis.
In conclusion, the findings of our study suggest that
the preventive approach should have somewhat different
goals in the prevention of CVD in patients with HIV/
AIDS in different age groups. In young people, especially
males, the fight against obesity, hypercholesterolemia
and metabolic syndrome are the main aims of preven-
tion. In individuals aged 40 years and over, the preven-
tion of obesity and hypercholesterolemia is also of great
importance. Moreover, the effects of uncontrolled
viremia and the prolonged use of HAART appear to be
more harmful in the older group. New therapeutic stra-
tegies with no atherogenic effects are urgently needed.
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